Auryxia is owned by Keryx Biopharms.
Auryxia contains Ferric Citrate.
Auryxia has a total of 15 drug patents out of which 1 drug patent has expired.
Expired drug patents of Auryxia are:
Auryxia was authorised for market use on 05 September, 2014.
Auryxia is available in tablet;oral dosage forms.
Auryxia can be used as control of serum phosphorus levels, control of serum phosphorous levels.
The generics of Auryxia are possible to be released after 21 July, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9328133 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
US9757416 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
US8338642 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
US7767851 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5753706 | KERYX BIOPHARMS | Methods for treating renal failure |
Feb, 2022
(1 year, 4 days ago) | |
US8299298 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Feb, 2024
(1 year, 10 days from now) | |
US8754257 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
US8609896 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
US9050316 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
US8846976 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
US8901349 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
US8754258 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 10 days from now) | |
US8093423 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Apr, 2026
(3 years from now) | |
US10300039 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(7 years from now) | |
US9387191 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(7 years from now) |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorous levels; Control of serum phosphorus levels
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic